Efficacy of adalimumab in moderate-to-severe pediatric crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2566-2571

  Viola, Franca ^a   Civitelli, Fortunata ^a   Di Nardo, Giovanni ^a   Barbato, Maria Beatrice ^a   Borrelli, Osvaldo ^a   Oliva, Salvatore ^a   Conte, Francesca ^a   Cucchiara, Salvatore ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLICULITIS; HUMAN; INJECTION SITE PAIN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; REMISSION; UPPER RESPIRATORY TRACT INFECTION; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; HOSPITALIZATION; INJECTION; TREATMENT OUTCOME;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CHILD; CROHN DISEASE; FEMALE; HUMANS; INJECTIONS; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350510116     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.372     Document Type: Article

References (41)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641-1657
2. Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2008; 2:105-124
3. Baumgart DC. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14:354-377
4. Griffiths A. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004; 18:509-523
5. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacolther 2007; 25:3-12
6. Jones J, Panaccione R. Biologic therapy in Crohn's disease: state of the art. Curr Opin Gastroenterol 2008; 24:475-481
7. Desilva S, Kaplan G, Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord 2008; 8:109-116
8. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebocontrolled trials. Clin Gastroenterol Hepatol 2008; 6:644-653
9. de Ridder L, Benninga MA, Taminiau JA et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 45:3-14
10. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542-553
11. Baert F, Norman M, Vermeire S et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608 (Pubitemid 36204954)
12. Loftus EV. Biologic therapy in Crohn's disease: review of the evidence. Rev Gastroenterol Disord 2007; 7 (Suppl 1):S3-S12
13. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333
14. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1239 (Pubitemid 47300424)
15. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65
16. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007; 146:829-838
17. Sandborn WJ. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord 2007; 7 (Suppl 2):S23-35
18. Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1683-1687
19. Wyneski MJ, Green A, Kay M et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 47:19-22
20. Rosh JR, Lerer T, Markowitz J. Retrospective evaluation of the safety and Effect of adalimumab therapy (reseat) in pediatric Crohn's disease. Gastroenterology 2008; 134 S1:A-657
21. Griffiths AM, Otley AR, Hyams J et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis 2005; 11:185-196
22. Bousvaros A, Antonioli DA, Colletti RB et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653-674
23. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A):5-36
24. Seiderer J, Brand S, Dambacher J. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacolther 2007; 25:787-796
25. Sandborn WJ, Hanauer S, Loft us EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99:1984-1989
26. Hinojosa J, Gomoll ?n N, Garc ?a S et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacolther 2007; 25:409-418
27. Chamouard P, Richert Z, Meyer N et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:882-887
28. Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opinther Targets 2008; 12:553-563
29. Faubion WA, Loft us EV, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260
30. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895-902
31. Markowitz J, Hyams J, Mack D et al. Pediatric IBD Collaborative Research Group. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1124-1129
32. Lewis JD, Gelfand JM, Troxel AB et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008; 103:1428-1435
33. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621-630
34. Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007; 9:513-520
35. Markowitz J. Current treatment of inflammatory bowel disease in children. Dig Liver Dis 2008; 40:16-21
36. Punati J, Markowitz J, Lerer T et al. Pediatric IBD Collaborative Research Group. Effect of early immunomodulator use in moderate to severe pediatric Crohn's disease. Inflamm Bowel Dis 2008; 14:949-954
37. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121-1125
38. Mackey AC, Green L, Liang LC et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265-267
39. Rosh JR, Gross T, Mamula P et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13:1024-1030
40. Cucchiara S, Escher JC, Hildebrand H et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009; 48:257-267
41. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861-8.